Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Nov 13;99(46):e23248.
doi: 10.1097/MD.0000000000023248.

The role of amplified in breast cancer 1 in breast cancer: A meta-analysis

Jianjing Hou  1   2 , Jingting Liu  3 , Mengci Yuan  4 , Chunyan Meng  5 , Jianhua Liao  5
Affiliations
Meta-Analysis

The role of amplified in breast cancer 1 in breast cancer: A meta-analysis

Jianjing Hou et al. Medicine (Baltimore). .

Abstract

Purpose: Amplified in breast cancer 1 (AIB1) expression is known to be involved in the initiation and progression of malignant breast cancer (BC), but its prognostic role remains uncertain. This meta-analysis assessed reported studies to evaluate this relationship.

Methods: Electronic databases were systematically reviewed to collect eligible studies using pre-established criteria. Hazard ratios (HRs) or odds ratios (ORs) and 95% confidence intervals (CIs) were pooled to estimate the impact of AIB1 protein expression on overall survival (OS) and clinicopathologic properties of BC cases.

Results: Nine eligible studies, including 6774 patients, were finally assessed by the current clinical meta-analysis. AIB1 positivity correlated with reduced OS (pooled HR = 1.409, 95% CI 1.159-1.714, P = .001). AIB1 overexpression also impacted prognosis as shown by univariate (pooled HR = 1.420, 95% CI 1.154-1.747, P = .001) and multivariate (pooled HR = 1.446, 95% CI 1.099-1.956; P = .009) analyses. Notably, subgroup analyses also revealed that AIB1 overexpression was associated with poor OS in some subgroups, such as ER-positive group (pooled HR = 1.511, 95% CI 1.138-2.006, P = .004), ER-positive without tamoxifen administration group (pooled HR = 2.338, 95% CI 1.489-3.627, P < .001), and premenopausal women group (pooled HR = 1.715, 95% CI 1.231-2.390, P = .001). Additionally, high AIB1 protein levels were associated with HER2 positivity (pooled OR = 0.331, 95% CI 0.245-0.448; P < .001), poorly differentiated histological grade (pooled OR = 0.377, 95% CI 0.317-0.448; P < .001), high Ki67 (pooled OR = 0.501, 95% CI 0.410-0.612; P < .001), presence of lymph node metastases (pooled OR = 0.866, 95% CI 0.752-0.997; P = .045), and absence of progesterone receptor (pooled OR = 1.447, 95% CI 1.190-1.759; P < .001).

Conclusions: This analysis demonstrated that AIB1 overexpression is related to aggressive phenotypes and unfavorable clinical outcomes in BC, and might involve in tamoxifen resistance. AIB1 may be a new prognostic biomarker and therapeutic target in BC.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Study selection process.
Figure 2
Figure 2
Clinical meta-analysis. A, Forest plot for overall survival by AIB1 protein expression. B, Forest plot for overall survival by AIB1 protein expression in univariate analysis. C, Forest plot for overall survival by AIB1 protein expression in multivariate analysis. AIB1 = amplified in breast cancer 1.
Figure 3
Figure 3
Sensitivity analysis was conducted by excluding each study in turn and recalculating the combined risk estimates for overall survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108. - PubMed
    1. Yuan M, Liao J, Luo J, et al. Significance of Vesicle-associated membrane protein 8 expression in predicting survival in breast cancer. J Breast Cancer 2018;21:399–405. - PMC - PubMed
    1. Dihge L, Bendahl PO, Grabau D, et al. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat 2008;109:255–62. - PubMed
    1. Guan XY, Xu J, Anzick SL, et al. Hybrid selection of transcribed sequences from microdissected DNA: isolation of genes within amplified region at 20q11-q13.2 in breast cancer. Can Res 1996;56:3446–50. - PubMed
    1. Tilghman SL, Sabnis G, Brodie AM. Upregulation of AIB1, aromatase and ERalpha provides long-term estrogen-deprived human breast cancer cells with a mechanistic growth advantage for survival. Hormone Mol Biol Clin Investigation 2011;3:357–66. - PMC - PubMed